December 23, 2016  |  Announcements, Education, Publications  |  By  |  0 Comments

Our CEO’s Top Three Takeaways from the 2016 ASH Meeting

We were fortunate to attend the American Society of Hematology mhematology2016covereeting earlier this month in San Diego. It brought together leading clinical scientists to present and discuss advances in malignant and non-malignant hematology.

Since the Cytobank platform is used by many who attended and presented, we were proud to see and be a small part of the exciting science. Highlights for us were:

  1. Remarkable success is being seen with CAR T cells in pediatric Acute Lymphoblastic Lymphoma (ALL)
    However, there’s still a long way to go towards durable responses for most patients in most lymphomas and leukemias. Also, there’s a great need to better understand the biology behind troubling side effects including cytokine release syndrome and neurotoxicity.  Which combination therapies will work best for which diseases?  
    The race is on and the clinical trials process will need to adapt to keep pace with the pull from patients and physicians for these therapies.
  2. Strong interest in the continued development of and correlation between genomic and cellular data for applications.
    This includes 
    measuring and characterizing the in vivo proliferation and persistence of CAR T cells post infusion, which could correlate to patient response and Minimal Residual Disease detection (MRD) which is used to guide treatment.  This is consistent with conversations with investigators at the meeting who are collecting and correlating single cell transcript and cytometry data.  
    Did you know: We are adding a .FCS to .CSV file converter to our platform early in the new year. If you are working to integrate genomic and proteomic data, we want to hear from you.
  3. Numerous posters and presentations featured Cytobank featured in infectious disease, immunological, and oncology applications
    The most common application was analysis related to deep profiling of the tumor microenviroment. Some great examples include:

    Deborah Czerwinski: Examining the Heterogeneity of Follicular Lymphoma By Multi-Parameter Flow Cytometry in Previously Untreated Patients (click image to expand)
    Homer Adams: High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action (click image to expand)

    viSNE for cell subset ID was the most frequent algorithm used,

    Cytobank viSNE plot featured in Identification of a clinically relevant population of Tregs in aplastic anemia. - Kordasti et al.
    Cytobank viSNE plot featured in Identification of a clinically relevant population of Tregs in aplastic anemia. – Kordasti et al.

    but we saw lots of SPADE, some CITRUS and combination use of SPADE on viSNE and also CITRUS being used to confirm results. It was exciting for us to see the use of multiple algorithms to make the most out of the data. We’ve included a few snapshots from the poster sessions showing other remarkable work that just so happened to feature some Cytobank analysis and visualizations.

    It certainly seems like an exciting time to being working in the field of Hematology with the dramatic progress that is being made. At Cytobank we look forward to the continued collaborations and partnerships that drive the science and drive our platform forward to assist in the most complex cellular analyses.

Cytobank’s own Hannah Polikowsky (on behalf of Vanderbilt) presents “Systems Immune Monitoring with Mass Cytometry Characterizes Altered Peripheral Immune Cell Environments in Patients with Chronic Graft Versus Host Disease”


Tom Coats of King’s College London presents: Mass Cytometry Reveals PD1 Upregulation Is an Early Step in MDS Disease Progression


ASH Poster - Stephen Oh
Stephen Oh of Washington University St. Louis presents: Mass Cytometry Analysis of Dysregulated Cytokine Production and Intracellular Signaling in Myelofibrosis.


Shovik Bandyopadhyay of Washington University St. Louis: Identification of Functionally Primitive and Immunophenotypically Distinct Subpopulations in Secondary Acute Myeloid Leukemia By Mass Cytometry.


Brent Ferrell of Vanderbilt presents: Expression of S100A9 in Bone Marrow Cells Differentiates Refractory Cytopenia with Multilineage Dysplasia (RCMD) from Refractory Anemia with Excess Blasts (RAEB) and Acute Myeloid Leukemia (AML)